Abstract: An integrated circuit (IC) device includes an interconnect layer including a first interconnect structure and a second interconnect structure spaced apart from the first interconnect structure in a first direction, the first interconnect structure and the second interconnect structure being arranged at a first pitch in the first direction; and a passivation structure on the first interconnect structure and the second interconnect structure. The passivation structure includes a first recess over the first interconnect structure; a second recess over the second interconnect structure; and a sloped region extending from the first recess to the second recess. A radius of curvature of a middle region of the sloped region is at least 0.5 times the first pitch.

Abstract: A Plinabulin micelle composition and a preparation method therefor are provided. Specifically, the Plinabulin micelle composition is essentially composed of Plinabulin, polyoxyl 15-hydroxystearate and propylene glycol. At least part of Plinabulin is encapsulated in the micelle, and can be mixed with a dextrose injection to obtain the Plinabulin micelle preparation for injection, which is used for the clinical treatment of tumor diseases. Both the Plinabulin micelle composition and the micelle preparation have an excellent electrochemical stability, dilution stability and storage stability.

Abstract: The present disclosures relate to compounds that can be useful as modulators of splicing factor RBM39. Also disclosed herein are pharmaceutical compositions that can include a compound of Formula (I), the use and preparation thereof.

Abstract: The disclosure provides for mass spectrometry (MS)-cleavable trioxane-based cross-linkers, and uses thereof, including for protein-protein interaction studies using cross-linking mass spectrometry.

Abstract: Disclosed herein are plinabulin and its use for treating a cancer or tumor characterized by expression of a mutant form of an epidermal growth factor receptor (EGFR) protein, comprising administering plinabulin to a subject in need thereof.

Abstract: Embodiments of the present disclosure relate to methods, compositions, and systems for proximity-based, photoactivated labeling of molecules. Molecules may be labeled via activation of a ligated photocatalyst capable of transmitting energy to a proximal biomolecular labeling agent. Depending on the activated half-life and diffusion coefficient of the labeling agent, molecules within a particular vicinity of the ligated photocatalyst may be labeled but molecules outside the vicinity will not be labeled.

Abstract: The disclosure provides for mass spectrometry (MS)-cleavable heterobifunctional photoactivated cross-linkers. The MS-cleavable heterobifunctional photoactivated cross-linkers can be used in mass spectrometry to facilitate structural analysis of intra-protein interactions in proteins and inter-protein interactions in protein complexes.

Abstract: Disclosed herein are compounds that can bind to tubulin and activate GEF-H1. Methods of using these compounds for treating cancer are also disclosed.

Abstract: Disclosed herein are plinabulin and the use for reducing neutropenia. Some embodiments relate to reducing the docetaxel induced neutropenia using plinabulin.

Abstract: Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

Abstract: Disclosed herein are methods of treating, preventing or ameliorating a disease or condition associated with cancer or a tumor. In some embodiments, the method includes administering a compound of Formula (I) to a subject in need thereof wherein the cancer or the tumor is or becomes resistant to one or more immune checkpoint inhibitors.

Abstract: Described herein are plinabulin unit dose forms, kits, and methods of preparing and using plinabulin. Some embodiments relate to the use of light-protective containers, light-protective packaging, light-protected IV bags, and light-protected IV tubing.